chronic iron overload
Haematology · 2006–2020
6decisions
1medicine
2carried consumer input
9individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| deferasirox Chronic iron overload due to disorders of haemopoiesis, including transfusion-dependent malignant and non-malignant disorders of erythropoiesis, and… | Nov 2020 | Recommended | none received |
| deferasirox Treatment of chronic iron overload due to disorders of haemopoiesis in patients who are transfusion dependent, non-transfusion dependent with thalassemia, or… | Jul 2018 | Recommended with restriction | 6 individuals |
| deferasirox Treatment of chronic iron overload associated with transfusion-dependent malignant disorders of erythropoiesis (myelodysplastic syndrome) and… | Jul 2015 | Deferred | 3 individuals |
| deferasirox Chronic iron overload in patients with non-malignant disorders of erythropoiesis who are transfusion-dependent. | Nov 2014 | Recommended with restriction | no section in document |
| deferasirox Chronic iron overload in adults, adolescents and children 6 years and older associated with disorders of erythropoiesis; Chronic iron overload in paediatric… | Jul 2006 | Recommended | no section in document |
| deferasirox Chronic iron overload associated with the treatment of disorders of erythropoiesis in adults, adolescents and children 6 years and older; and in paediatric… | Jul 2006 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.